Alembic Pharma gets FDA approval for Solifenacin Succinate tablets
Category: #healthcare  By Akshay Kedari  Date: 2019-05-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alembic Pharma gets FDA approval for Solifenacin Succinate tablets
  • The FDA approval was awarded to Solifenacin Succinate tablets’ abbreviated new drug application (ANDA).
  • The pharmaceutical firm now holds a total of 94 ANDA approvals from the US health regulator.

Alembic Pharmaceuticals Ltd., (Alembic Pharma), a renowned Indian multinational pharmaceutical firm, has reportedly announced that its overactive bladder treatment tablets, Solifenacin Succinate, have received approval from the United States Food and Drug Administration (USFDA).

Reports cite, the approved drug is a biosimilar that is therapeutically equivalent to Vesicare tablets, a reference listed drug developed by the U.S. arm of Japanese pharmaceutical firm, Astellas Pharma Inc. (Astellas).

According to a press release by Alembic Pharma, similar to Vesicare, the Solifenacin Succinate tablets would be made available to customer in two doses, 5 mg and 10 mg. The tablets are muscarinic antagonist that are indicated for the treatment of an overactive bladder that shows symptoms of urgency, urge urinary incontinence as well as urinary frequency.

Quoting sales data from reliable sources, the company stated that the Solifenacin Succinate tablets, both in doses of 5 mg and 10 mg boast of a market size that is estimated to be approximately $967 million for a period of 12 months which ended in December 2018.

The pharmaceutical firm now reportedly holds a total of 94 ANDA approvals from the US health regulator. Alembic Pharmaceuticals’ shares were trading at approximately INR 533.40 each, up by approximately 0.77% on the Bombay Stock Exchange (BSE) following the drug’s approval.

About Alembic Pharmaceuticals:

Alembic Pharmaceuticals Ltd. is a vertically integrated research & development pharmaceutical firm and has been a prominent player in the healthcare sector since 1907. The company is publicly listed and is especially known for manufacturing & marketing generic pharmaceutical products throughout the world. The firm boasts of its state-of-the-art research & development (R&D) facilities that have been approved by the regulatory authorities of several developed nations, which also includes the United States FDA.

Source Credit:

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-overactive-bladder-treatment-drug/articleshow/69423547.cms

https://www.alembicpharmaceuticals.com/wp-content/uploads/2019/05/Press-Release-USFDA-Approval-Solifenacin-Succinate-Tablets-May-2019.pdf

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Guangzhou Automobile investment in Nio will be capped at $150m
Guangzhou Automobile investment in Nio will be capped at $150m
By Akshay Kedari

Nio had indicated an urgent need to secure funds and early talks with Guangzhou Auto   ...

Moderna adds two candidates in new autoimmune therapeutic area
Moderna adds two candidates in new autoimmune therapeutic area
By Akshay Kedari

Moderna, Inc., a Cambridge, Massachusetts-based biotechnology firm that is focused on drug discovery...

Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
By Akshay Kedari

Survival rate for stage II colon cancer is about 58 to 88% and patients will gain from additional tr...